An In-depth Summary of Recent Artificial Intelligence Applications in Drug Design

• URL: http://arxiv.org/abs/2110.05478v1
• Date: Sun, 10 Oct 2021 00:40:53 GMT
• Title: An In-depth Summary of Recent Artificial Intelligence Applications in Drug Design
• Authors: Yi Zhang
• Abstract summary: From the year 2017 to 2021, the number of applications of several recent AI models in drug design increases significantly. This survey includes the theoretical development of the previously mentioned AI models and detailed summaries of 42 recent applications of AI in drug design.
• Score: 5.365309795469097
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: As a promising tool to navigate in the vast chemical space, artificial intelligence (AI) is leveraged for drug design. From the year 2017 to 2021, the number of applications of several recent AI models (i.e. graph neural network (GNN), recurrent neural network (RNN), variation autoencoder (VAE), generative adversarial network (GAN), flow and reinforcement learning (RL)) in drug design increases significantly. Many relevant literature reviews exist. However, none of them provides an in-depth summary of many applications of the recent AI models in drug design. To complement the existing literature, this survey includes the theoretical development of the previously mentioned AI models and detailed summaries of 42 recent applications of AI in drug design. Concretely, 13 of them leverage GNN for molecular property prediction and 29 of them use RL and/or deep generative models for molecule generation and optimization. In most cases, the focus of the summary is the models, their variants, and modifications for specific tasks in drug design. Moreover, 60 additional applications of AI in molecule generation and optimization are briefly summarized in a table. Finally, this survey provides a holistic discussion of the abundant applications so that the tasks, potential solutions, and challenges in AI-based drug design become evident.

Related papers

• Generative AI Agent for Next-Generation MIMO Design: Fundamentals, Challenges, and Vision [76.4345564864002]
  Next-generation multiple input multiple output (MIMO) is expected to be intelligent and scalable. We propose the concept of the generative AI agent, which is capable of generating tailored and specialized contents. We present two compelling case studies that demonstrate the effectiveness of leveraging the generative AI agent for performance analysis.
  arXiv  Detail & Related papers  (2024-04-13T02:39:36Z)
• A Survey of Generative AI for de novo Drug Design: New Frontiers in Molecule and Protein Generation [8.9311469963107]
  Generative models for de novo drug design focus on the creation of novel biological compounds entirely from scratch. Rapid development in the field, combined with the inherent complexity of the drug design process, creates a difficult landscape for new researchers to enter. In this survey, we organize de novo drug design into two overarching themes: small molecule and protein generation.
  arXiv  Detail & Related papers  (2024-02-13T16:56:31Z)
• Neural scaling laws for phenotypic drug discovery [3.076170146656896]
  We investigate if scale can have a similar impact for models designed to aid small molecule drug discovery. We find that DNNs explicitly supervised to solve tasks in the Pheno-CA do not continuously improve as their data and model size is scaled-up. We introduce a novel precursor task, the Inverse Biological Process (IBP), which is designed to resemble the causal objective functions that have proven successful for NLP.
  arXiv  Detail & Related papers  (2023-09-28T18:10:43Z)
• ImDrug: A Benchmark for Deep Imbalanced Learning in AI-aided Drug Discovery [79.08833067391093]
  Real-world pharmaceutical datasets often exhibit highly imbalanced distribution. We introduce ImDrug, a benchmark with an open-source Python library which consists of 4 imbalance settings, 11 AI-ready datasets, 54 learning tasks and 16 baseline algorithms tailored for imbalanced learning. It provides an accessible and customizable testbed for problems and solutions spanning a broad spectrum of the drug discovery pipeline.
  arXiv  Detail & Related papers  (2022-09-16T13:35:57Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• A Survey on Non-Autoregressive Generation for Neural Machine Translation and Beyond [145.43029264191543]
  Non-autoregressive (NAR) generation is first proposed in machine translation (NMT) to speed up inference. While NAR generation can significantly accelerate machine translation, the inference of autoregressive (AR) generation sacrificed translation accuracy. Many new models and algorithms have been designed/proposed to bridge the accuracy gap between NAR generation and AR generation.
  arXiv  Detail & Related papers  (2022-04-20T07:25:22Z)
• Deep Denerative Models for Drug Design and Response [0.0]
  Recent success of deep generative modeling holds promises of generation and optimization of new molecules. We present commonly used chemical and biological databases, and tools for generative modeling.
  arXiv  Detail & Related papers  (2021-09-14T06:33:56Z)
• Artificial Intelligence in Drug Discovery: Applications and Techniques [33.59138543942538]
  Various AI techniques have been used in a wide range of applications, such as virtual screening and drug design. We first give an overview on drug discovery and discuss related applications, which can be reduced to two major tasks. We then discuss common data resources, molecule representations and benchmark platforms.
  arXiv  Detail & Related papers  (2021-06-09T20:46:44Z)
• Artificial Intelligence based Autonomous Molecular Design for Medical Therapeutic: A Perspective [9.371378627575883]
  Domain-aware machine learning (ML) models have been increasingly adopted for accelerating small molecule therapeutic design. We present the most recent breakthrough achieved by each of the components, and how such autonomous AI and ML workflow can be realized.
  arXiv  Detail & Related papers  (2021-02-10T00:43:46Z)
• A Systematic Approach to Featurization for Cancer Drug Sensitivity Predictions with Deep Learning [49.86828302591469]
  We train >35,000 neural network models, sweeping over common featurization techniques. We found the RNA-seq to be highly redundant and informative even with subsets larger than 128 features.
  arXiv  Detail & Related papers  (2020-04-30T20:42:17Z)
• Rethinking Generalization of Neural Models: A Named Entity Recognition Case Study [81.11161697133095]
  We take the NER task as a testbed to analyze the generalization behavior of existing models from different perspectives. Experiments with in-depth analyses diagnose the bottleneck of existing neural NER models. As a by-product of this paper, we have open-sourced a project that involves a comprehensive summary of recent NER papers.
  arXiv  Detail & Related papers  (2020-01-12T04:33:53Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.